Ivak P 1

1. Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial
2. First Clinical Experience With the Pressure Sensor-Based Autoregulation of Blood Flow in an Artificial Heart
3. Concomitant Surgical Procedures and Aspirin Avoidance With Left Ventricular Assist Device Therapy
4. Bioprosthetic Total Artificial Heart Implantation Does Not Induce Chronic Inflammation
5. Bioprosthetic Total Artificial Heart in Autoregulated Mode Is Biologically Hemocompatible: Insights for Multimers of von Willebrand Factor
6. Progressive endothelial coverage enhances hemocompatibility and prevents calcification in bioprosthetic valve tissue
7. Intermediate-dose prophylactic anticoagulation with low molecular weight heparin is safe after bioprosthetic artificial heart implantation
8. Understanding Platelet Activation in the Aeson Bioprosthetic Total Artificial Heart: Insights From Aspirin Treatment and Outcomes
9. Impact of Atrial Fibrillation, Diabetes Mellitus, and Obesity on Outcomes With Aspirin Avoidance and Hemocompatibility With a Left Ventricular Assist Device: An Analysis From the ARIES-HM3 Trial
1